A preference trial with naratriptan 2,5 mg and paracetamol 1000 mg in migraine patients in the general practice.

Completed

• Registration Number: NL-OMON22893

Brief Summary

/A

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 40

Inclusion Criteria

1. The subject is older than 18 years of age at visit 1;

2. The subject has a current history of migraine with or without aura according to the IHS criteria;

Exclusion Criteria

1. Subjects with a history suggestive of ischemic heart disease (IHD), (e.g. angina pectoris) or any atherosclerotic disease which places them at increased risk of coronary ischaemia;

2. Subjects with a history of cerebrovascular accident (CVA) or transient ischaemic attack (TIA);

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Direction and strength of patient preference on a 10 cm scale ranging from -5 (strong preference for treatment A) to + 5 (strong preference for treatment B), where 0 indicates no preference.

Secondary Outcome Measures

Name	Time	Method
1. Changes in quality of life;<br /><br>2. Pain free rate at 2 hours postdose.